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Hsei-Wei Wang2,3,5,6*Abstract
Background: Endothelial progenitor cells (EPCs) play a fundamental role in post-natal vascular repair, yet EPCs from
different anatomic locations possess unique biological properties. The underlying mechanisms are unclear.
Results: EPCs from CB expressed abundant genes involved in cell cycle, hypoxia signalling and blood vessel
development, correlating with the phenotypes that CB-EPCs proliferated more rapidly, migrated faster, and formed
tubule structure more efficiently. smRNA-seq further deciphered miRNome patterns in EPCs isolated from CB or PB:
54 miRNAs were enriched in CB-EPCs, while another 50 in PB-EPCs. Specifically, CB-EPCs expressed more angiogenic
miRNAs such as miR-31, while PB-EPCs possessed more tumor suppressive miRNAs including miR-10a. Knocking
down miR-31 levels in CB-EPCs suppressed cell migration and microtubule formation, while overexpressing miR-31
in PB-EPCs helped to recapitulate some of CB-EPC functions.
Conclusions: Our results show the foundation for a more detailed understanding of EPCs from different anatomic
sources. Stimulating the expression of angiogenic microRNAs or genes in EPCs of low activity (such as those from
patients with cardiovascular diseases) might allow the development of novel therapeutic strategies.Background
The progressive impairment of endothelial function and
integrity starts a cascade of events, leading to microcir-
culation damage, atherosclerosis and common cardio-
vascular disease (CVD), such as coronary heart disease
(CHD), myocardial infarction (MI), heart failure, stroke
and peripheral arterial disease (PAD) [1]. Blood-derived
endothelial progenitor cells (EPCs) represent the “pro-
moters” of vascular repair providing the rationale for au-
tologous stem cell therapy [2]. The coexistence of
multiple classical CVD risk factors negatively influences
the number and functional activity of EPCs [3,4]. The
number of EPCs has been reported to negatively* Correspondence: hwwang@ym.edu.tw
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reproduction in any medium, provided the orcorrelate with hypertension, diabetes mellitus and aging
but not smoking [5]. Levels of EPCs are inversely corre-
lated to progression of coronary heart disease [6]. EPCs
are currently being tested in different clinical settings in-
cluding repair of damaged microcirculation, regeneration
of ischemic tissues, and bioengineering of vascular grafts
(www.clinicaltrials.gov/).
Clinically, circulating EPCs can be obtained from adult
peripheral blood and umbilical cord blood. The number
of EPCs in adult blood is known to be significantly lower
than in cord blood [7]. EPCs derived from different ana-
tomic locations, just like other somatic stem cells of dif-
ferent sources [8,9], possess unique biological activities:
in vitro phenotypic studies demonstrated that CB-EPCs
have competitive advantage compared with PB-EPCs
due to their higher proliferative advantage, as well as
better survival rate upon stress-induced apoptosis
[10,11]. In vivo, tissue-engineered blood vessels gener-
ated by peripheral blood- and umbilical cord blood-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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blood EPCs are unstable and regress within weeks, while
umbilical cord blood EPCs form normal-functioning
blood vessels that last for more than 4 months [11,12].
Thus, umbilical cord blood EPCs hold great therapeutic
potential for cell therapy and vascular engineering.
The above findings suggest that CB-EPCs have en-
hanced vasculogenic ability compared with adult PB-EPCs.
However, the underlying mechanisms are unclear. EPCs
from human umbilical cord and adult peripheral blood
activate different mechanisms upon high-dose x-ray radia-
tion treatment: CB-EPCs undergo p53 stabilization,
Bax-dependent apoptosis and p21-dependent G1 and G2/M
cell cycle checkpoints, while PB-EPCs undergo only
radiation-induced senescence [13], indicating unique
gene expression patterns in EPCs of different sources.
Another level of regulation may lie on microRNAs
(miRNAs), which are endogenously expressed small non-
coding RNAs of 18-24 nucleotides in length that regu-
late gene expression on the posttranscriptional level [14].
microRNAs have emerged as master regulators of stem cell
lineage differentiation and angiogenesis [14]. microRNAs
also play a crucial role in endothelial inflammation,
senescence and susceptibility to atherosclerosis: endothe-
lial inflammation is critically regulated by miRNAs such
as miR-126 and miR-10a, and endothelial aging is
additionally controlled by miR-217 and miR-34a [15].
miR-221 and miR-222, which are encoded from the same
miRNA cluster, modulate the angiogenic properties
of human umbilical vein endothelial cells (HUVECs) by
targeting c-Kit and endothelial nitric oxide synthase
(eNOS) [16]. In contrast, miRNA-31 enhances endothelial
cell migration and invasion by targeting FAT4, a novel
breast cancer tumor suppressor [17,18]. miR-126, -132,
-296, -378, and the miR-17 ~ 92 cluster (encoding miR-17,
-18a, -19a/b, -20a and miR-92a) also contribute to
pathological angiogenesis [19-21].
In this study we explored protein-coding mRNAs and
miRNAs involved in EPC activities. We found that CB-
EPCs migrate faster and form tubule structures in vitro
more efficiently than PB-EPCs do. mRNA and miRNA
levels in EPCs of different origins reflect their unique
performance.
Methods
Isolation and cultivation of EPCs
All patients gave informed consent, and the study was
approved by the research ethics committee of the
Hsinchu Mackay Memorial Hospital, Taiwan (ref num-
ber: 11MMHIS040). Protocols of this study were con-
sistent with ethical guidelines provided in the 1975
Helsinki Declaration (http://www.wma.net/e/policy/b3.
htm). EPC isolation and characterization were done as
described previously with minor modifications [22,23].In brief, blood mononuclear cells (MNCs) isolated by
Histopaque-1077 (1.077 g/ml, Sigma, St. Louis, Missouri,
USA) density-gradient centrifugation. MNCs (1 × 107)
were plated in 2 ml endothelial growth medium-2
(Lonza Ltd., Basel, Switzerland), with supplementation
(hydrocortisone, IGF-1, human EGF, human VEGF,
human FGF-B, ascorbic acid, GA-1000, heparin and 2%
fetal bovine serum) on fibronectin-coated six-well plates
at 37 °C in a 5% CO2 incubator. After 3 days of cultur-
ing, nonadherent cells were removed. Thereafter, the
medium were replaced every 2 days, and EPCs colonies
emerge 2–4 weeks after the start of MNC culture.
EPC tube formation, transwell cell migration and cell
proliferation assays
A miR-31 cDNA construct was used in overexpression
experiments [18]. Tube formation assay was performed
on EPCs to assess their capacity for vasculogenesis,
which is believed to be important in new vessel forma-
tion. In brief, the in vitro tube formation assay was per-
formed by thawing Matrigel at 4 °C overnight, and then
placed it in a 96-well plate at 37 °C for 1 h to allow the
matrix solution to solidify. EPCs were harvested with
trypsin/EDTA, and 1 × 104 EPCs were placed on Matri-
gel with EGM-2 medium or serum-free DMEM and
incubated at 37 °C for 6 h. Tubule formation was
inspected under an inverted light microscope (100x).
Four representative fields were taken. For 3D angiogen-
esis assay, collagen type I acidic solution were mixed
with 1/2 volume of basic conditioned medium with 0.2
ug/ml SDF-1α (R&D system, Minneapolis, MN USA)
and solidify 30 minutes in 96-well plate at 37 °C in a 5%
CO2 incubator. 10
5 cells per well were seeded and
assayed.
Cell migration ability was evaluated using Costar
TranswellW Polycarbonate Permeable Supports (Corning,
NY, USA) as previously described [18]. The degree of
cell proliferation was examined by the MTT assay sys-
tem (Invitrogen, USA) according to the manufacturer’s
instructions.
mRNA microarray and bioinformatics analysis
Total RNA sample preparation, cRNA probe prepar-
ation, array hybridization and data analysis were done as
described previously [24]. AffymetrixTM HG-U133 Plus
2.0 whole genome chips were used. RMA log expression
units were calculated from Affymetrix GeneChip array
data using the ‘affy’ package of the Bioconductor (http://
www.bioconductor.org) suite of software for the R statis-
tical programming language (http://www.r-project.org).
The default RMA settings were used to background cor-
rect, normalize and summarize all expression values.
Significant differences between the sample groups was
identified using the ‘limma’ (Linear Models for
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and an empirical Bayesian moderated t-statistic hypoth-
esis test between the two specified phenotypic groups
was performed [25]. To control for multiple testing
errors, we then applied a false discovery rate algorithm
to these p values in order to calculate a set of q values,
thresholds of the expected proportion of false positives,
or false rejections of the null hypothesis [26]. Heat maps
were created by the dChip software (http://www.dchip.
org/). Array data are deposited in the Gene Expression
Omnibus (GEO) database with an accession number of
GSE39763. Part of the PB EPC array data were from a
public GEO dataset GSE23203 (GSM663476-81) and 1
CB-EPC data from GSE12891 (GSM323169).
Gene annotation was performed by our ArrayFusion
web tool (http://microarray.ym.edu.tw/tools/arrayfusion/
) [27]. Gene Ontology database search were performed
by the DAVID 6.7 Bioinformatics Resources (http://
david.abcc.ncifcrf.gov/). The Ingenuity Pathway Analysis
(IPA) web tool developed by Ingenuity Co. (http://www.
ingenuity.com) was used to construct functional regula-
tory networks of gene profiles. IPA uses the Ingenuity
Pathways Knowledge Base to identify known interactions
between focus genes and other genes that are not in the
gene list. IPA then determines a statistical score for each
network according to the fit of the network to the set of
focus genes. The score is the negative log of p and
denotes the likelihood of the focus genes in the network
being found together by chance.Small RNA sequencing (smRNA-Seq) and data analysis
Total RNA was collected and small RNA fractions were
sequenced by Illumina Solexa Genome Analyzer IIx
(GAIIx; Illumina, San Diego, CA USA) according to
manufacturer’s instruction. For data analysis, quality
Fastq sequences, which were without poly-A, ambiguous
nucleotides or a 5’ adapter, yet flanking 6-18 nt of 3’
adapter sequence, had the adapter sequences trimmed
and the identical sequences were then collapse to unique
sequences. The resulting unique sequences that did not
align to mRNA database (UCSC genome browsers) but
were aligned to known microRNA sequences (miRBase
R18; http://www.mirbase.org/) were subjected into fur-
ther quantification analysis. Sequencing reads were cal-
culated to obtain a RPKM (reads per kilobase of exon
model per million mapped reads) [28] value as C/LMN
x 109, where C = read numbers aligned to given miRNA
chromosomal region, L = length of miRNA, M = mul-
tiple mapping numbers across all miRNA regions and N
= total read numbers that map to human genome se-
quence. microRNA target prediction was done by the
miRTar webtool (http://mirtar.mbc.nctu.edu.tw/human/)
[29].RNA extraction and real-time quantitative polymerase
chain reaction (qPCR)
RNA extraction and reverse transcription were performed
as previously described [18]. The expression of mature
human miRNAs was determined by a stem-loop real-time
PCR system using the appropriate primer pairs. The uni-
versal PCR reverse primer for the miRNAs was 5’-
GTGCAGGGTCCGAGGT-3’. miR-31-specific primers
were used [18] and the primer sequences are in Additional
file 1: Figure S1. Primer sequences of all other genes and
miRNAs are also in Additional file 1: Figure S1. The
miRNA expression data were normalized against the aver-
age values of U6 snRNA, U48 snRNA and 5S rRNA, while
the miRNA expression data were normalized against the
average values of GAPDH and beta-actin.
Results
Isolation and characterization of human EPCs from cord
blood and adult peripheral blood
EPCs were obtained from cord blood or peripheral blood
of healthy subjects as described [23]. Blood MNCs that
were initially seeded on fibronectin-coated wells were
round, and outgrowth EPCs with a cobblestone-like
morphology similar to mature endothelial cells grew to
confluence at days 14-21 (not shown). Cultured EPCs
were subjected into Traswell cell migration assays
(Figure 1A), tube formation assays (Figure 1B), or MTT
assays (Figure 1C). Clearly EPCs from CB migrated fas-
ter, proliferated faster and formed microvasculature
structure more efficient in vitro (Figure 1A-C).
Gene expression signatures and functional modules of
different EPCs
To provide the underlying mechanisms for observed
phenotypes, we explored the transcriptome patterns of
different EPCs. Protein-coding mRNAs were deciphered
first by Affymetrix whole-genome microarrays. A total of
753 probe sets (positive false discovery rate (pFDR) q <
0.005) were found unique to CB-EPC, while another 431
to PB-EPC (Figure 2A & Additional file 2: Figure S2 on-
line). A PCA plot using these 1184 probe represents
their differentiating power (Figure 2B).
The above gene list gave us a primary insight into the
unique composition of differential EPCs but reflected lit-
tle on EPC functions. To understand more how gene ex-
pression profiles might correlate with EPC biology and
to provide quantitative evidence, signature probe sets
were subjected to Gene Ontology (GO) database search
for finding statistically over-represented functional
groups within these genes. Given that the whole human
transcriptome was represented by the microarray ana-
lysis, this analysis was not biased toward the coverage of
the microarray. The GO categories of the biological pro-








Figure 1 Different angiogenic abilities between EPCs isolated from different anatomic locations. (A) EPCs from cord blood (CB-EPCs)
migrate faster than those from adult peripheral blood (PB-EPCs). EPCs from different sources were subjected to Transwell cell migration assays,
and migrated cells were stained (representative pictures are shown) and counted (left panel, n = 3). *:P < 0.05 (B) CB-EPCs form better
microvasculature structures in vitro. EPCs were subjected onto MatriGel for tube formation assays (representative pictures are shown). Tube
lengths of formed microvascular structure were counted (left panel, n = 3). *:P < 0.05 (C) Cell proliferation assays show CB-EPCs grow faster in vitro.
Cultured EPCs were subjected into MTT assays for monitoring cell proliferation rate.
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most significant biological process for CB-EPCs is cell
cycle (349 genes, p = 1.14 × 10-3), especially the mitotic
cell cycle (19 genes, p = 1.41 × 10-4; Figure 2C). Vascula-
ture development genes (16 genes, p = 1.01 × 10-2), es-
pecially those involved in angiogenesis (10 genes, p =
3.73 × 10-2), are also significantly higher in CB-EPCs
(Figure 2C). The abundant expression of CB-EPC or PB-
EPC genes were verified by RT-qPCR (Figure 2D). A
famous tumor suppressor TP53 was more abundant in
PB-EPC, while angiogenic genes ANGPTL4 and CDK1
in CB-EPCs (Figure 2D). Other related predominant
processes include those pertaining to DNA damage
checkpoint (8 genes, p = 5380 × 10-4, not shown), pro-
tein transport (38 genes, p = 0.0034), and post-
translational protein modification (53 genes, p = 0.0045,
especially those involve in phosphorylation (37 genes,
p = 0.0124)).
We also subjected CB-EPC genes into KEGG and In-
genuity Pathway Analysis (IPA) database search for dis-
closing enriched pathways and functional modules.
More information was revealed from Ingenuity database
search. The “G2/M DNA damage checkpoint regulation”
canonical pathway ranks the No. 1 most significant path-
way found among CB-EPC genes (Figure 2E). Genes
involved in the “FLT3 signaling in hematopoietic pro-
genitor cells” pathway is also overexpresssed in CB-EPCs
(Figures 2E-F). Also enriched in CB-EPCs are HIF1α(hypoxia-inducible transcription factor 1 alpha) signal-
ing, cardiac hypertrophy signaling, renin-angiotensin sig-
naling and NFAT in cardiac hypertrophy pathways
(Figure 2E), reflecting the pro-angiogenic nature of CB-
EPCs. By KEGG definition, genes involved in cell cycle
are again found significant (Additional file 3: Figure S3).
Database search and functional module assays explain in
part why CB-EPCs amplification quicker (Figure 1C).
Unique miRNA expression profiles of different EPCs
revealed by small RNA sequencing (smRNA-Seq)
Another level of gene expression regulation is through
microRNAs. To provide a more comprehensive view of
transcriptome profiles of EPCs from different sources,
we determined miRNA profiles of different EPCs by se-
quencing the small RNA fractions of both EPCs. Illu-
mina Solexa platform generated 9.7 million high-quality
sequence reads for PB-EPCs, and another 11 million
reads for CB-EPCs (Figure 3A, upper). We constructed
an in-house pipeline (illustrated in Figure 3A) for analyz-
ing sequencing data. The initial operations included
identifying sequence matches to the mRNA database in
order to eliminate degraded mRNA exon reads. Then
non-exonic reads that match previously annotated miR-
NAs deposited in the miRBase database (release 18)
were subjected to normalization and quantitative profil-
ing. The expression of known miRNAs were converted












Figure 2 Distinct gene expression patterns of different EPCs. (A) A heat map showing genes more abundant in CB-EPCs. Columns represent
EPC samples from different donors, while rows represent probe sets. Genes in red: increased expression; in blue: decreased. (B) A principle
component analysis (PCA) plot using genes differentially expressed between different EPCs. Each spot represents a single array sample. (C) The
unique biological functions of CB-EPCs. CB-EPC-enriched genes were subjected to a Gene Ontology (GO) database search. These categories were
selected from the “Biological Process” organizing principle in the GO database (http://www.geneontology.org/). The number of genes, gene
symbols, and p values for each category that are significantly enriched are listed (p < 0.05). (D) Validation of mRNA array data by qPCR. Mean
gene expression levels of EPC genes were compared to the average CT values of GAPDH and beta-actin controls. Results are expressed as
mean± standard deviation. *:P < 0.05 (E) Canonical pathways enriched in CB-EPCs according to the analysis of the Ingenuity Pathway Analysis
(IPA) web tool. (F) Schematic representation of the “FLT3 Signaling in Hematopoietic Progenitor Cells” pathway. CB-EPC genes assigned to this
pathway are indicated and in red.
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between 2 EPCs, with 54 being more abundant in CB-
EPCs while another 50 in PB-EPCs (≥1.5 folds;
Figure 3B & Tables 1-2). The differential expression of
miR-31, miR-18a, miR-10a and miR-26a were verified by
RT-qPCR (Figures 3C-D).
Applying the genetic network analysis function in the
IPA web tool, we searched for miRNA-mRNA pairs and
networks in CB-EPCs. PB-EPC miRNAs, such as miR-10a/b, miR-26a, miR-103a, miR-107, miR-139-5p, miR-
151b, miR-361-5p, miR-365 and miR-1290, were found
to be master regulators of a subset of CB-EPC protein-
coding mRNAs (Figure 3E). The collective reduction of
these miRNAs in CB-EPCs may explain in part why
genes, such as ETV1 (Figure 3E), in this genetic network
are more abundant in CB-EPCs.
Most of the differentially expressed miRNAs have not






































Figure 3 Differentially expressed miRNAs between CB- and PB-EPCs discovered by smRNA-Seq. (A) A table summarizes reads number
(upper) and a flowchart describes the data analysis pipeline for quantification of known miRNAs from smRNA-Seq data (lower). (B) Differential
expressed miRNAs between cord blood EPCs and adult peripheral blood EPCs. (C-D) qPCR validation of smRNA-Seq data. Mean miRNA
expression levels were compared to the average CT values of U6 snRNA+U48 snRNA+ 5S rRNA controls. miRNAs more abundant in CB-EPC
(C) or PB-EPC (D) were verified. *:P < 0.05 (E) A major functional genetic network composed of multiple PB-EPC microRNAs (in green) and CB-EPC
genes (in red). This network is displayed graphically as nodes (gene products) and edges (biological relationships between nodes) mapped by
the Ingenuity Pathway Analysis (IPA) tool. The intensity of the node color indicates the degree of differential expression. Hub miRNAs in this
genetic network are shown.
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reduced in the plasma of type 2 diabetes patients, which
intend to have poor angiogenesis [31]. In vitro, miR-503
expression in ECs is upregulated in culture conditions
mimicking diabetes mellitus (high D-glucose) and
ischemia-associated starvation (low growth factors).Forced miR-503 expression inhibits EC proliferation, mi-
gration, and network formation on Matrigel [32]. MiR-
24 is considerably upregulated after cardiac ischemia
and is enriched in cardiac endothelial cells. MiR-24
induces endothelial cell apoptosis, abolishes endothelial
capillary network formation on Matrigel, and inhibits
Table 1 54 miRNAs over-expressed in CB-EPC
Name chromosome location PB RPKM CB RPKM Fold (CB/PB) PB rank CB rank
hsa-mir-136 chr14:101351053-101351075 0 495.64316 9.90E+307 770 95
hsa-mir-376c chr14:101506069-101506089 1.2448007 1174.4226 943.4623551 483 68
hsa-mir-494 chr14:101496018-101496039 3.3418648 3083.2217 922.6051575 382 33
hsa-mir-376a* chr14:101507125-101507146 3.1190746 2104.9521 674.8643011 389 47
hsa-mir-376a chr14:101506455-101506475 0.7002004 359.68243 513.6849822 542 106
chr14:101507162-101507182
hsa-mir-377 chr14:101528431-101528452 0.89116406 305.87003 343.2252755 514 116
hsa-mir-410 chr14:101532298-101532318 1.4004008 399.5301 285.2969664 468 101
hsa-mir-381 chr14:101512305-101512326 6.6837296 1888.779 282.5935687 316 54
hsa-mir-411 chr14:101489677-101489697 5.134803 1427.5367 278.0119705 341 63
hsa-mir-889 chr14:101514286-101514306 1.4004008 309.84427 221.2539939 468 113
hsa-mir-379 chr14:101488408-101488428 27.541208 4422.998 160.5956427 221 27
hsa-mir-369-3p chr14:101531978-101531998 5.6016035 868.6908 155.0789519 334 81
hsa-mir-134 chr14:101521031-101521052 10.9167595 910.0818 83.36556283 281 77
hsa-mir-29b chr7:130562226-130562248 84.74453 6061.3887 71.52542707 162 20
chr1:207975795-207975817
hsa-mir-222* chrX:45606479-45606500 25.843756 1562.2592 60.45016057 223 61
hsa-mir-31 chr9:21512157-21512177 347.53278 15717.314 45.22541442 93 7
hsa-mir-127-3p chr14:101349372-101349393 64.60941 2614.9524 40.47324376 174 39
hsa-mir-654-3p chr14:101506606-101506627 16.932117 517.527 30.5648136 255 91
hsa-mir-146a chr5:159912379-159912400 1061.7109 7229.664 6.809446903 65 15
hsa-mir-216a chr2:56216155-56216176 462.73697 3054.6147 6.601190089 84 34
hsa-mir-18b chrX:133304114-133304136 95.57735 621.04553 6.497831652 152 90
hsa-mir-24-2* chr19:13947140-13947161 126.99086 810.7064 6.383974406 144 84
hsa-mir-503 chrX:133680401-133680423 83.323845 498.72934 5.985433581 163 94
hsa-mir-18a chr13:92003010-92003032 116.24848 684.41486 5.887516637 147 87
hsa-mir-4792 chr3:24562903-24562920 56.91072 308.37952 5.418654341 181 114
hsa-mir-19a chr13:92003193-92003215 168.31697 886.21814 5.265174034 130 80
hsa-mir-19b chrX:133303713-133303735, 351.0184 1759.4749 5.01248624 92 58
chr13:92003499-92003521
hsa-mir-185 chr22:20020676-20020697 130.77832 639.70306 4.891506941 142 89
hsa-mir-424 chrX:133680710-133680731 326.61172 1557.3126 4.768085481 97 62
hsa-mir-24 chr9:97848346-97848367 39987.26 172634.36 4.317234039 5 2
chr19:13947103-13947124
hsa-mir-196a chr17:46709894-46709915 93.497955 398.9361 4.266789578 156 102
chr12:54385546-54385567
hsa-mir-130a chr11:57408725-57408746 319.70517 1143.3563 3.576283424 98 70
hsa-mir-345 chr14:100774213-100774234 137.23924 455.79385 3.321162737 138 98
hsa-mir-32 chr9:111808552-111808573 94.68617 312.1079 3.296235343 153 112
hsa-mir-339-3p chr7:1062591-1062613 116.35501 376.72174 3.237692472 146 105
hsa-mir-186 chr1:71533364-71533385 1265.8989 3930.9248 3.105243871 57 30
hsa-mir-20b chrX:133303880-133303902 393.07117 1119.9288 2.849175634 90 72
hsa-mir-542-3p chrX:133675394-133675415 302.77307 758.6524 2.505679914 100 85
hsa-mir-877 chr6:30552109-30552128 134.05331 333.61777 2.488694759 140 110
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Table 1 54 miRNAs over-expressed in CB-EPC (Continued)
hsa-mir-106b chr7:99691666-99691686 1116.7422 2731.2852 2.445761609 62 36
hsa-mir-452 chrX:151128150-151128171 466.9701 1105.1763 2.366696069 82 73
hsa-mir-22 chr17:1617208-1617229 1037.9835 2326.5046 2.24136954 66 42
hsa-mir-374a* chrX:73507130-73507151 1247.1844 2619.4692 2.100306258 60 38
hsa-mir-29c chr1:207975210-207975231 1326.5715 2675.448 2.01681402 53 37
hsa-mir-29a chr7:130561507-130561528 1443.6847 2802.1428 1.940965919 50 35
hsa-mir-30e chr1:41220043-41220064 5007.227 9227.503 1.842836963 26 10
hsa-mir-99a chr21:17911421-17911442 2773.0786 5025.056 1.812085673 41 24
hsa-mir-20a chr13:92003326-92003348 1287.8253 2302.079 1.787570876 54 43
hsa-mir-15a chr13:50623303-50623324 483.79068 822.4292 1.699969086 81 83
hsa-mir-100 chr11:122022983-122023004 4361.801 7380.455 1.692065961 28 14
hsa-mir-106a chrX:133304274-133304296 1250.3193 2036.8033 1.629026521 59 50
hsa-mir-17 chr13:92002872-92002894 1266.1599 2058.4065 1.625708175 56 48
hsa-mir-27a chr19:13947261-13947281 5321.171 8077.8022 1.51804973 25 12
hsa-mir-140-5p chr16:69967006-69967027 334.1866 501.82477 1.501630436 96 93
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of the stemness transcription factor GATA2 and the
p21-activated kinase PAK4 [33,34]. MiR-100 has an anti-
angiogenic function by modulating proliferation, tube
formation, and sprouting activity of endothelial cells and
migration of vascular smooth muscle cells and functions
as an endogenous repressor of the serine/threonine pro-
tein kinase mammalian target of rapamycin (mTOR)
[35]. MiR-29b can suppress tumor angiogenesis, invasion
and metastasis by regulating MMP-2 expression in hepa-
tocellular carcinoma (HCC) [36]. MicroRNAs from the
miR-17 ~ 92 cluster are known to contribute in patho-
logical angiogenesis [19-21], and 5 out of 6 members (in-
cluding miR-17, -18a, -19a/b and -20a) were
overexpressed in CB-EPCs (Table 1).miR-31 as a novel EPC angiogenic miRNA
To identify more pro-angiogenic miRNAs involved in
EPC activity, we examined which miRNA(s) may
contribute in EPC angiogenesis. MiR-31 is a known pro-
angiogenic and pro-lymphangiogenic miRNA which
induce motility in both matured blood vessel and lymph-
atic endothelial cells [18,37]. Knocking down endogen-
ous miR-31 levels reduced tube formation and cellular
migration abilities in CB-EPCs (Figures 4A-C), suggest-
ing a pro-angiogenic role of miR-31 in both progenitor
and mature type endothelial lineage cells. On the
other hand, overexpressing miR-31 in PB-EPCs helped
to recapitulate some of the functions of CB-EPCs
(Figure 4D). Over-expressing miR-31 in PB-EPC or
knocking down endogenous CB-EPC miR-31 level did
not affect cell proliferation rate at a significant level in
the first 24 hours of transfection (Additional file 4:Figure S4). The tube formation and cell migration effects
we observed should due to mainly the pro-angiogenic
activity of miR-31.Discussion
Endothelial cells from the internal barrier of the vascula-
ture, and play fundamental roles in vascular develop-
ment and disease. The regulation of angiogenesis
depends not only on the number of circulating EPC but
also on their functions [38]. Aberrant EPC activity and
the resulting abnormal angiogenesis cause a variety of
diseases, such as ischemia, cancer and metastasis. On
the other hand, these cells are also potential cell source
for cellular therapies aiming to enhance the neovascular-
ization of tissue engineered constructs or ischemic tis-
sues [39]. Atherosclerotic heart disease remains one of
the major causes of morbidity and mortality worldwide.
Currently, vascular revascularization techniques, includ-
ing balloon angioplasty and stenting, have been well
developed. However, post-angioplasty restenosis substan-
tially limit long-term benefits of heart revascularization
procedures. Therapeutic progenitor cell transplantation
bear potential for organ vascularization regeneration in
various pathological states [40]. The application of EPC
in stenting technology during vascular revascularization
is the Genous EPC stent (OrbusNeich, Wanchai, Hong
Kong), which is a stainless-steel stent coated with immo-
bilized human anti-CD34 monoclonal antibodies that
allow the stent surface to "capture" EPCs in the blood to
accelerate endothelialization of the stent strut. In recent
clinical trial, it shows promise result in reducing the risk
of stent thrombosis by facilitating rapid endothelializa-
tion on stent strut [41].
Table 2 50 miRNAs over-expressed in PB-EPC
Name chromosome location PB RPKM CB RPKM Fold (CB/PB) PB rank CB rank
hsa-let-7b* chr22:46509625-46509646 358.35938 26.206163 -13.67462226 91 280
hsa-mir-15b* chr3:160122433-160122454 695.9995 72.2731 -9.630132096 73 215
hsa-mir-1290 chr1:19223572-19223590 337.0359 35.74031 -9.43013365 95 258
hsa-mir-15b chr3:160122395-160122416 2379.7402 379.11118 -6.27715648 42 104
hsa-mir-574-3p chr4:38869713-38869734 435.55652 86.03938 -5.062292639 85 201
hsa-mir-25 chr7:99691194-99691215 1534.8059 319.06284 -4.810356167 49 111
hsa-mir-148a chr7:25989542-25989563 1073.8528 231.33844 -4.641912516 63 134
hsa-mir-30e* chr1:41220085-41220106 3634.1675 920.4779 -3.948131183 34 76
hsa-mir-30a* chr6:72113257-72113278 4051.6772 1061.4753 -3.817024475 29 74
hsa-mir-365 chr16:14403197-14403218, 653.44617 171.86374 -3.802117713 75 149
chr17:29902497-29902518
hsa-mir-28-3p chr3:188406622-188406643 1804.1597 485.26227 -3.717906401 44 96
hsa-mir-23b chr9:97847547-97847567 8076.4937 2225.3198 -3.629363159 22 45
hsa-mir-146b-5p chr10:104196277-104196298 1253.9794 349.96533 -3.583153223 58 108
hsa-mir-92b chr1:155165028-155165049 318.21985 90.19796 -3.528016044 99 195
hsa-mir-197 chr1:110141562-110141583 528.68317 149.92363 -3.526349849 79 156
hsa-mir-140-3p chr16:69967045-69967065 12527.033 3577.7405 -3.501381109 12 32
hsa-mir-598 chr8:10892731-10892752 489.91757 143.68575 -3.40964619 80 161
hsa-let-7b chr22:46509571-46509592 8703.284 2554.5288 -3.407001714 20 40
hsa-mir-378 chr5:149112430-149112450 32406.646 10804.972 -2.999234612 7 9
hsa-mir-455-3p chr9:116971767-116971787 548.25714 187.93459 -2.917276378 78 142
hsa-mir-193b chr16:14397874-14397895 415.28253 143.25558 -2.898892525 87 162
hsa-mir-92a chrX:133303574-133303595 3847.525 1331.7456 -2.889084071 33 64
chr13:92003615-92003636
hsa-mir-93 chr7:99691438-99691460 3588.8904 1322.95 -2.712793681 35 65
hsa-let-7c chr21:17912158-17912179 15608.78 5758.0083 -2.710794981 11 22
hsa-mir-30b chr8:135812813-135812834 1066.1298 400.58517 -2.661431026 64 100
hsa-mir-10a chr17:46657266-46657288 17177.37 6494.583 -2.644876507 8 17
hsa-mir-10b chr2:177015057-177015079 16707.91 6317.509 -2.644699042 10 19
hsa-let-7d chr9:96941123-96941144 9057.177 3642.2817 -2.48667669 16 31
hsa-mir-151-3p chr8:141742686-141742706 17066.672 7218.801 -2.3641976 9 16
hsa-mir-30c chr1:41222972-41222994 4914.325 2188.866 -2.245146574 27 46
chr6:72086706-72086728
hsa-let-7e chr19:52196046-52196067 8924.559 3985.3586 -2.239336505 17 29
hsa-mir-320a chr8:22102488-22102509 757.8811 340.61673 -2.225026058 70 109
hsa-let-7a chr11:122017276-122017297 65673.34 30296.24 -2.16770596 3 5
chr9:96938244-96938265
chr22:46508632-46508653
hsa-mir-99b chr19:52195871-52195892 8875.32 4099.9907 -2.164717105 19 28
hsa-let-7f chr9:96938635-96938656 37668.82 17587.143 -2.141838501 6 6
chrX:53584207-53584228
hsa-mir-23a chr19:13947409-13947429 10271.966 4879.2725 -2.105224908 14 26
hsa-mir-125b chr21:17962573-17962594 3983.9465 1976.1088 -2.016056252 30 51
chr11:121970517-121970538
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hsa-mir-125a-5p chr19:52196521-52196544 1764.7084 897.535 -1.966172238 46 79
hsa-mir-361-5p chrX:85158686-85158707 399.24158 205.20401 -1.945583714 89 138
hsa-mir-16 chr3:160122542-160122563 3338.2983 1761.0107 -1.895671787 38 57
chr13:50623163-50623184
hsa-mir-1307 chr10:105154058-105154079 553.6359 294.46994 -1.880110072 77 118
hsa-mir-320b chr1:224444751-224444772 661.5061 356.97238 -1.853101632 74 107
chr1:117214409-117214430
hsa-mir-217 chr2:56210155-56210177 10865.332 5983.509 -1.815879612 13 21
hsa-mir-769-5p chr19:46522219-46522240 421.96628 236.17818 -1.786643796 86 133
hsa-mir-191 chr3:49058105-49058127 3378.5552 1927.2273 -1.753065246 36 52
hsa-mir-139-5p chr11:72326147-72326168 301.21347 178.96194 -1.683114689 101 145
hsa-mir-26a chr12:58218441-58218462 3344.9814 2055.193 -1.627575318 37 49
chr3:38010904-38010925
hsa-mir-103a chr5:167987909-167987931 8117.7095 5296.3853 -1.532688624 21 23
chr20:3898188-3898210
hsa-mir-107 chr10:91352513-91352535 3862.0547 2533.423 -1.524441319 31 41
hsa-mir-151b chr14:100575775-100575792 610.3607 405.608 -1.504804392 76 99
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or angiomiRs, play a crucial role in regulating various
aspects of cancer biology, including angiogenesis. Ma-
nipulating miRNAs in the settings of pathological
vascularization therefore represents a new therapeutic
approach [14]. On the other hand, there are still chal-
lenges to harnessing EPCs for cell therapy. One of these
is their rarity (0.01-0.02 per 106 mononuclear cells),
which makes EPC isolation challenging. In vitro cultiva-
tion and amplification of EPCs is therefore required be-
fore these cells may be appropriately investigated for use
in clinical therapies. However, it is crucial to maintain
EPC activity during such in vitro manipulation. Under-
standing the basic EPC biology will help to develop new
biomarkers for monitoring EPC activities. In this report,
we identified EPCs, especially those from cord blood, ex-
ploit several cellular genetic groups and miRNA
pathways to regulate their angiogenesis activities. Tran-
scriptome information will eventually help to develop
new clinical applications as mentioned above.
When PB-EPC genes were subjected into GO database
search, we found these genes are enriched in both Wnt re-
ceptor signaling (8 genes including CREBBP, DVL3,
NFAT5, PPARD, RAC1, TBL1X, TCF7L2, TP53; p= 0.019)
and positive regulation of I-kappaB kinase/NF-kappaB
cascade (6 genes including LITAF, MAP3K3, MAP3K7IP2,
MUL1, TRIM13, PSMB7; p = 0.048). Genes involved in
the induction of apoptosis are also more abundant in PB-
EPCs (15 genes, p = 0.006). KEGG and IPA database
search also revealed that genes involved in both Wnt sig-
naling (p = 0.020) and MAPK (13 genes, includingACVR1B, ARRB1, DDIT3, DUSP3, DUSP16, ELK4,
GADD45B, MAP3K3, MAP3K7IP1, MAP3K7IP2, MAP-
KAPK2, RAC1 and TP53; p = 012) pathways are more
abundant in PB-EPCs (Additional file 5: Figure S5, Add-
itional file 6: Table S1). IPA analysis also revealed the
Wnt/β-catenin signaling pathway may be more active in
PB-EPCs (Additional file 7: Table S2). The Wnt signaling
system regulates vascular patterning in the developing
embryo [42]. It has recently been documented that Wnt1
is a proangiogenic molecule of human endothelial pro-
genitor function, and increases blood flow to ischemic
limbs in a HGF-dependent manner [43]. Our work further
supports a crucial role of Wnt pathway in adult EPCs, and
Wnt proteins may be therapeutically deployed to increase
blood flow and angiogenesis in adult ischemic tissues.
In this study we applied RNA sequencing (RNA-seq)
technology, instead of microRNA chips, for deciphering
EPC miRNomes. This is due to the fact that microarray
application in miRNome research has several limitations,
including hybridization and cross-hybridization artifacts,
dye-based detection issues and design constraints that
preclude or seriously limit the detection of newly discov-
ered miRNAs or previously unmapped, novel miRNAs
[44]. These issues have made it difficult for standard
array designs to provide full sequence comprehensive-
ness (coverage of all possible genes, including “un-
known” ones, in large genomes) or transcriptome
comprehensiveness (reliable detection of all RNAs of all
prevalence classes, including the least abundant ones
that are physiologically relevant). Studies using this






Figure 4 miR-31 is involved in EPC activities. (A-C) Knocking down endogenous miR-31 in CB-EPCs. Anti-miR-31 antagomiR or the siGFP
control (Ctrl) was introduced into CB-EPCs by electroporation, and 2 days later EPCs were subjected to tube formation (A) and Transwell cell
migration assays (B). Cellular miR-31 levels were detected by RT-qPCR (C, left panel; n = 3), and migration assay and tube formation assay results
were also quantified (C, middle and right panels; n = 3, using cells from 3 batches of donors). (D) Overexpressing miR-31 in PB-EPCs stimulates
EPC angiogenic abilities. Cellular miR-31 levels were detected by RT-qPCR (left panel; n = 3). Cellular migration assays and tube formation assays
were done, and results were quantified (middle and right panels; n = 3, using cells from 3 batches of donors).
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http://www.biomedcentral.com/1471-2164/13/447complexity of eukaryotic transcriptomes [44]. RNA-seq
has also delivered a sharp rise in the rate of novel micro-
RNA discovery in the current miRBase R18 release
(2011 Nov; http://microrna.sanger.ac.uk/sequences/),
which is the primary online repository for all microRNA
sequences and annotation.
One of the CB-EPC-dominant microRNAs is miR-31,
a pro-angiogenic miRNA that enhances endothelial cell
migration [18,37]. MiR-31 has recently been documen-
ted as a signature BEC miRNA that negatively regulates
lymphatic endothelial cell identity and lymphatic vascu-
lar development by targeting Prox1, a transcription fac-
tor that functions as a master regulator of lymphaticlineage-specific differentiation [45]. In the present study,
we further showed that miR-31 is a dominant miRNA in
CB-EPCs, and its overexpression is crucial for EPCs to
possess superior angiogenic ability (Figure 4). Unmask-
ing the roles of small RNA-mediated gene regulation in
EPC activity will be crucial and will provide new insights
into regenerative and reparative medicine. We envision
that our report will serve as a resource for future
miRNA studies that aim to improve understanding of
the various regulatory ultimately modulating EPC and
EC activities.
For miRNAs more abundant in PB-EPCs, miR-217 modu-
lates endothelial cell senescence via silent information
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http://www.biomedcentral.com/1471-2164/13/447regulator 1 (sirT1) [46]. The levels of miR-330 and let-7e
are higher in the myocardial microvascular endothelial
cells (MMVEC) in type 2 diabetic Goto-Kakizaki (GK)
rats, which have impaired angiogenesis [47]. MiR-93,
member of the miR-106b  25 cluster (a paralog of
the miR-17  92 cluster), in tumor cells possesses onco-
genic and angiogenic activities [48]. Both microRNA-
125a-5p and miR-125b are overexpressed in PB-EPCs
(Table 2), and their role in inhibiting endothelin-1 ex-
pression in vascular endothelial cells has been reported
[49]. miR-10a regulates a proinflammatory phenotype in
athero-susceptible endothelium in vivo [50]. The col-
lective effects of these miRNAs in EPC biology are still
awaited to be elucidated.
Conclusions
In summary, our results reveal a series of differentially
expressed miRNAs and protein-coding genes that have
not previously been associated with EPC biology. This
study therefore provides a road map for future mechan-
istic studies of EPC migration and microvasculature for-
mation, which should eventually help to improve our
understanding of angiogenesis, and will also benefit the
development of new therapeutic approaches that target
the inhibition of pathogenic angiogenesis in tumors, the
stimulation of angiogenesis in patients with cardiovascu-
lar diseases, stroke or diabetes.
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